© Copyright - Newspaper WordPress Theme by TagDiv
Formoterol Fumarate
Also known as / Synonyms: Formoterol Fumarate Dihydrate, Eformoterol, LABA
Long-acting beta-2 agonist (LABA) bronchodilator providing 12-hour airway opening in asthma and COPD.
Clinical Snapshot & Specifications
Approved Indications & Medical Uses
- Long-term maintenance treatment of asthma in patients 5 years and older (strictly combined with an inhaled corticosteroid).
- Maintenance treatment of bronchoconstriction in patients with chronic obstructive pulmonary disease (COPD), including chronic bronchitis and emphysema.
- Prevention of exercise-induced bronchospasm (EIB) in adults and adolescents.
Contraindications (Do Not Use If…)
- Monotherapy without a long-term asthma controller (such as an inhaled corticosteroid) is contraindicated in asthma.
- Treatment of acute status asthmaticus or acute severe asthma exacerbations where emergency intensive rescue therapy is required.
- Known hypersensitivity to formoterol or formulation components.
Important Clinical Precautions & Warnings
- Asthma-related death risk: LABAs used as monotherapy increase the risk of asthma-related death; formoterol must always be prescribed with an inhaled corticosteroid (ICS).
- Paradoxical bronchospasm: may occur with an immediate increase in wheezing after dosing; treat immediately with an inhaled short-acting bronchodilator and discontinue formoterol.
- Cardiovascular effects: can produce tachycardia, palpitations, arrhythmia, and ECG changes (QTc prolongation).
- Hypokalemia and hyperglycemia: transient beta-2 adrenergic stimulation can lower serum potassium and elevate blood glucose.
- Do not exceed recommended dose: fatal cardiac events have been reported with excessive beta-agonist inhalation.
Special Populations (Paediatric & Geriatric Care)
Pediatric: Approved for asthma maintenance in children >= 5 years strictly in conjunction with an inhaled corticosteroid. Geriatric: No dose adjustments needed, but monitor cardiovascular status closely.
Side Effects & Adverse Reactions
Common Side Effects (Usually Mild)
Tremor, headache, palpitations, nasopharyngitis, insomnia, throat irritation, dry mouth, and muscle cramps.
Serious Side Effects — Seek Urgent Medical Care
Paradoxical bronchospasm, severe cardiac arrhythmias (ventricular extrasystoles, atrial fibrillation), myocardial ischemia, significant QTc prolongation, and severe hypokalemia.
Action: Discontinue medication and seek immediate medical attention or call emergency services if any serious symptom occurs.
Drug, Food & Substance Interactions
- Other beta-agonists: concurrent use increases sympathetic stimulation and cardiovascular adverse events.
- Beta-blockers (propranolol, timolol): antagonize formoterol bronchodilation and may produce severe bronchospasm in asthmatic patients.
- Diuretics (loop/thiazides): co-administration can potentiate acute hypokalemia.
- Monoamine oxidase inhibitors (MAOIs) and tricyclic antidepressants: prolong QTc interval and potentiate cardiovascular toxicity; administer with extreme caution.
Pregnancy & Lactation Clinical Safety
Pregnancy Safety:
Use with caution — see notesFormoterol may interfere with uterine contractility during labor due to beta-2 tocolytic effects. There are no well-controlled studies in pregnant women; use only if potential benefit justifies potential risk.
Lactation & Breastfeeding:
Use with caution — see notesExcretion in human breast milk is unknown, though detected in animal milk. Administer cautiously to nursing mothers.
Storage, Administration & Overdose Protocol
🌡️ Recommended Storage:
Store inhalation powder capsules at 20°C to 25°C (68°F to 77°F). Protect from moisture and heat. Do not swallow rotacaps; administer via dry powder inhaler only.
⏱️ Missed Dose Protocol:
Take the missed inhalation as soon as remembered. Never take more than 2 capsules at a time, and do not exceed 24 mcg total daily dose.
Overdose leads to exaggerated beta-agonist effects: extreme tachycardia, angina, tremors, hypertension or hypotension, severe hypokalemia, and cardiac arrest. Discontinue use and administer cardioselective beta-blockers with extreme caution under ICU monitoring.
Clinical Sources & Regulatory References
Statutory drug monograph citations and regulatory databases consulted for clinical synthesis.
Every clinical monograph on 4mg.in is continuously cross-referenced against official pharmacopoeias, national formulary compendia, and statutory regulatory filings to guarantee therapeutic precision:
Central Drugs Standard Control Organisation, Ministry of Health and Family Welfare. Evaluated for approved indications, Schedule H/H1 status, and National List of Essential Medicines (NLEM).
CDSCO Official Portal →U.S. Food and Drug Administration Approved Prescribing Information, Package Inserts, and Pharmacovigilance Black Box Warnings repository via NLM DailyMed.
Search FDA Labels on DailyMed →WHO Model List of Essential Medicines (23rd List) and WHO Collaborating Centre for Drug Statistics Methodology (Anatomical Therapeutic Chemical - ATC / DDD Index).
WHO Essential Medicines Registry →National Center for Biotechnology Information (NCBI). Peer-reviewed clinical trials, bioavailability investigations, and Cochrane systematic reviews.
Query PubMed Studies for Formoterol Fumarate →
4mg Clinical Pharmacology Team. Formoterol Fumarate Monograph: Uses, Dosage, Contraindications & Interactions. Medically reviewed by licensed clinical editors. 4mg.in, 2026. Available at: https://4mg.in/medicines/formoterol/
